

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-16. (Canceled)

17. (Currently Amended) ~~Use of~~ A method for treating chronic lymphocytic leukemia (CLL) in a mammalian subject comprising administering to said subject an effective amount of an isolated monoclonal antibody that specifically binds to a polypeptide comprising the sequence set forth in SEQ ID NO: 4 in the manufacture of a medicament for treatment of a hematological malignancy in a mammalian subject.

18.-20. (Canceled)

21. (Currently Amended) The method ~~use of~~ claim 17 ~~or 18~~, wherein said antibody is a humanized antibody.

22. (Currently Amended) The method ~~use of~~ claim 17 ~~or 18~~, wherein said antibody is a chimeric antibody.

23. (Currently Amended) The method ~~use of~~ claim 17 ~~or 18~~, wherein said antibody is a Fab fragment.

24. (Currently Amended) The ~~use~~ method of claim 17 ~~or 18~~, wherein said antibody is a Fv fragment.

25. (Currently Amended) The method ~~use~~ of claim 17-~~or~~-18, wherein said antibody is a scFv.

26. (Currently Amended) The method ~~use~~ of claim 17-~~or~~-18, wherein said antibody further comprises a therapeutic moiety.

27. (Currently Amended) The method ~~use~~ of claim 26, wherein the therapeutic moiety is a radionuclide.

28. (Currently Amended) The method ~~use~~ of claim 27, wherein the radionuclide is a member selected from the group consisting of: ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{211}At , and ^{212}Bi .

29.-31. (Canceled)

32. (Currently Amended) The ~~use~~-method of claim 17-~~or~~-18, wherein the mammalian subject is a human.

33. (Currently Amended) The ~~use~~-method of claim 17-~~or~~-18, wherein the administration is intravenous.

34.-53. (Canceled)